NCT03693326View on ClinicalTrials.gov

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

PHASE2UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2022

Conditions
CancerLung Cancer MetastaticImmunotherapy
Interventions
DRUG

PDR001

PDR001 300 mg (fixed dose) intraveneously every 3 weeks

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT03693326 - PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities | Biotech Hunter | Biotech Hunter